"Drug Synergism" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
The action of a drug in promoting or enhancing the effectiveness of another drug.
| Descriptor ID |
D004357
|
| MeSH Number(s) |
G07.690.773.968.477
|
| Concept/Terms |
Drug Synergism- Drug Synergism
- Drug Synergisms
- Synergism, Drug
- Synergisms, Drug
Drug Potentiation- Drug Potentiation
- Drug Potentiations
- Potentiation, Drug
- Potentiations, Drug
Drug Augmentation- Drug Augmentation
- Augmentation, Drug
- Augmentations, Drug
- Drug Augmentations
|
Below are MeSH descriptors whose meaning is more general than "Drug Synergism".
Below are MeSH descriptors whose meaning is more specific than "Drug Synergism".
This graph shows the total number of publications written about "Drug Synergism" by people in this website by year, and whether "Drug Synergism" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1996 | 0 | 4 | 4 |
| 1997 | 0 | 3 | 3 |
| 1998 | 0 | 3 | 3 |
| 1999 | 0 | 3 | 3 |
| 2000 | 0 | 4 | 4 |
| 2001 | 0 | 4 | 4 |
| 2002 | 0 | 2 | 2 |
| 2003 | 0 | 6 | 6 |
| 2004 | 0 | 5 | 5 |
| 2005 | 0 | 2 | 2 |
| 2006 | 0 | 9 | 9 |
| 2007 | 0 | 3 | 3 |
| 2008 | 0 | 9 | 9 |
| 2009 | 0 | 6 | 6 |
| 2010 | 0 | 4 | 4 |
| 2011 | 0 | 3 | 3 |
| 2012 | 0 | 3 | 3 |
| 2013 | 0 | 7 | 7 |
| 2014 | 0 | 3 | 3 |
| 2015 | 0 | 6 | 6 |
| 2016 | 0 | 10 | 10 |
| 2017 | 0 | 9 | 9 |
| 2018 | 1 | 4 | 5 |
| 2019 | 1 | 11 | 12 |
| 2020 | 0 | 9 | 9 |
| 2021 | 0 | 6 | 6 |
| 2025 | 0 | 1 | 1 |
| 2026 | 0 | 1 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Drug Synergism" by people in Profiles.
-
Aminoglycosides enhance meropenem/vaborbactam activity against KPC-producing Klebsiella pneumoniae in the hollow fiber infection model. Antimicrob Agents Chemother. 2026 Apr; 70(4):e0136525.
-
Polo-like kinase 1 inactivation enhances PI3K inhibition-mediated apoptosis of NOTCH1-mutant head and neck squamous cell carcinoma. Cancer Lett. 2025 Aug 10; 625:217814.
-
Neratinib kills B-RAF V600E melanoma via ROS-dependent autophagosome formation and death receptor signaling. Pigment Cell Melanoma Res. 2022 01; 35(1):66-77.
-
Curcumin-laden hyaluronic acid-co-Pullulan-based biomaterials as a potential platform to synergistically enhance the diabetic wound repair. Int J Biol Macromol. 2021 Aug 31; 185:350-368.
-
Therapeutic Synergy in Esophageal Cancer and Mesothelioma Is Predicted by Dynamic BH3 Profiling. Mol Cancer Ther. 2021 08; 20(8):1469-1480.
-
Combined Inhibition of Rad51 and Wee1 Enhances Cell Killing in HNSCC Through Induction of Apoptosis Associated With Excessive DNA Damage and Replication Stress. Mol Cancer Ther. 2021 07; 20(7):1257-1269.
-
Overcoming T-cell exhaustion in LCH: PD-1 blockade and targeted MAPK inhibition are synergistic in a mouse model of LCH. Blood. 2021 04 01; 137(13):1777-1791.
-
Cooperative Targeting of Immunotherapy-Resistant Melanoma and Lung Cancer by an AXL-Targeting Antibody-Drug Conjugate and Immune Checkpoint Blockade. Cancer Res. 2021 04 01; 81(7):1775-1787.
-
Synergism between Angiotensin receptors ligands: Role of Angiotensin-(1-7) in modulating AT2 R agonist response on nitric oxide in kidney cells. Pharmacol Res Perspect. 2020 12; 8(6):e00667.
-
Unbiased High-Throughput Drug Combination Pilot Screening Identifies Synergistic Drug Combinations Effective against Patient-Derived and Drug-Resistant Melanoma Cell Lines. SLAS Discov. 2021 06; 26(5):712-729.